Evidence map›Paper›PMID 36961560›Full record

ArticlePsychopharmacology2023

Effects of DPTQ, a novel positive allosteric modulator of the dopamine D1 receptor, on spontaneous eye blink rate and spatial working memory in the nonhuman primate.

Stacy A Castner, Linli Zhang, Charles R Yang, Junliang Hao, Jeffrey W Cramer, Xushan Wang, Robert F Bruns, Hugh Marston, Kjell A Svensson, Graham V Williams

Open access · hybridAbstract read
In one paragraph

Article in Psychopharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Stacy A CastnerDepartment of Comparative Medicine, Yale University, 310 Cedar St, New Haven, CT, 06520, USA.
Linli ZhangChemPartner, 99 Lian He North Road, Zhe Lin Town, Fengxian Area, Shanghai, China.
Charles R YangChemPartner, 99 Lian He North Road, Zhe Lin Town, Fengxian Area, Shanghai, China.
Junliang HaoEli Lilly & Co, Lilly Corporate Center, Indianapolis, IN, 46285, USA.
Jeffrey W CramerEli Lilly & Co, Lilly Corporate Center, Indianapolis, IN, 46285, USA.
Xushan WangEli Lilly & Co, Lilly Corporate Center, Indianapolis, IN, 46285, USA.
Robert F BrunsEli Lilly & Co, Lilly Corporate Center, Indianapolis, IN, 46285, USA.
Hugh MarstonEli Lilly & Co, Erlwood, Sussex, UK.
Kjell A SvenssonEli Lilly & Co, Lilly Corporate Center, Indianapolis, IN, 46285, USA.
Graham V WilliamsDepartment of Comparative Medicine, Yale University, 310 Cedar St, New Haven, CT, 06520, USA. graham.williams@yale.edu.ORCID http://orcid.org/0000-0001-7885-5568
Eli Lilly (United States) · USYale University · USEli Lilly (United Kingdom) · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

rationaleDopamine (DA) signaling through the D1 receptor has been shown to be integral to multiple aspects of cognition, including the core process of working memory. The discovery of positive allosteric modulators (PAMs) of the D1 receptor has enabled treatment modalities that may have alternative benefits to orthosteric D1 agonists arising from a synergism of action with functional D1 receptor signaling.

objectivesTo investigate this potential, we have studied the effects of the novel D1 PAM DPTQ on a spatial delayed response working memory task in the rhesus monkey. Initial studies indicated that DPTQ binds to primate D1R with high affinity and selectivity and elevates spontaneous eye blink rate in rhesus monkeys in a dose-dependent manner consistent with plasma ligand exposures and central D1activation.

resultsBased on those results, DPTQ was tested at 2.5 mg/kg IM in the working memory task. No acute effect was observed 1 h after dosing, but performance was impaired 48 h later. Remarkably, this deficit was immediately followed by a significant enhancement in cognition over the next 3 days. In a second experiment in which DPTQ was administered on days 1 and 5, the early impairment was smaller and did not reach statistical significance, but statistically significant enhancement of performance was observed over the following week. Lower doses of 0.1 and 1.0 mg/kg were also capable of producing this protracted enhancement without inducing any transient impairment.

conclusionsDPTQ exemplifies a class of D1PAMs that may be capable of providing long-term improvements in working memory.

Indexed as

Memory, Short-TermReceptors, Dopamine D1AnimalsDopamineDopamine AgonistsSpatial MemoryDopamineDopamine AgonistsReceptors, Dopamine D1Cyclic AMPD1DopamineEye blinkPlasticityPositive allosteric modulatorSpatial delayed responseWorking memory

Identifiers

PMID36961560
PMCPMC10102062
OpenAlexW4360817627

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.